Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib, and Dexamethasone Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma

NCT02219178 is registered in ClinicalTrials.gov with Cancer Trials Ireland as lead sponsor.

NCT NCT02219178
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02219178 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib, and Dexamethasone Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma
Lead sponsor
Cancer Trials Ireland
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2014
Completion date
April 30, 2020
Enrollment
42 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma